Sotagliflozin Limits Platelet Clotting in Laboratory Study

Dual SGLT Inhibition Reduces Platelet Aggregation in Lab Models

Sotagliflozin prevents excessive blood platelet activation in laboratory blood samples and animal models, according to research from the University of Michigan Medical School published in the Journal of Clinical Investigation. Excessive platelet activation leads to blood clots that can obstruct arterial blood flow to the heart and brain.

The Food and Drug Administration (FDA) previously approved sotagliflozin under the brand name Inpefa to treat adults with heart failure, as well as people with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors.

The medication belongs to the sodium-glucose cotransporter (SGLT) inhibitor class, which lowers blood sugar by preventing glucose reabsorption. While standard SGLT2 inhibitors target proteins in the kidneys, sotagliflozin inhibits both SGLT2 in the kidneys and SGLT1 in other organs.

Comparing Sotagliflozin to Single Target SGLT2 Inhibitors

Researchers compared sotagliflozin directly against empagliflozin, a widely prescribed medication sold as Jardiance that targets only SGLT2. In blood samples gathered from both healthy volunteers and individuals with type 2 diabetes, sotagliflozin limited platelet activation, whereas empagliflozin produced little to no measurable effect.

In mice with injured blood vessels, sotagliflozin reduced blood clot formation by approximately 60 percent. In contrast, empagliflozin reduced clot formation by 5 to 10 percent in the same animal model.

Over 20 percent of people with type 2 diabetes take SGLT2 inhibitors, but clinical trials have noted that sotagliflozin also reduced ischemic events such as heart attacks and strokes. The laboratory comparison indicates that blocking SGLT2 proteins alone does not stop platelet aggregation.

Mechanisms Beyond SGLT1 Blocking in Platelets

Genetically removing SGLT1 proteins from mouse platelets reduced blood clot formation by approximately 40 percent in the study. However, neither genetic removal nor an SGLT1-selective inhibitor drug named mizagliflozin matched the 60 percent reduction achieved by sotagliflozin.

The study authors concluded that sotagliflozin appears to prevent clotting through additional biological pathways beyond direct SGLT1 inhibition on platelets. The researchers noted that SGLT1 proteins on endothelial cells lining blood vessels may also alter platelet behavior, though this mechanism requires further study.

Selective SGLT1 inhibitors with higher potency can trigger gastrointestinal side effects. The authors noted that sotagliflozin balances SGLT1 and SGLT2 inhibition without generating the severe digestive complaints seen with higher-affinity SGLT1 compounds.

Clinical Scope and Study Caveats

These mechanistic findings stem from laboratory cell cultures and mouse vascular injury models rather than human clinical endpoints. While sotagliflozin has demonstrated reduced ischemic risk in earlier clinical trials, laboratory clotting data cannot predict exact risk reductions for individual patients.

Heart disease remains a leading cause of complication and mortality for people living with type 2 diabetes. Patients managing type 2 diabetes, chronic kidney disease, or heart failure should talk to their clinician about whether dual SGLT inhibition fits their broader cardiovascular treatment plan.